ARKG vs WDNA
ARK Genomic Revolution ETF against WisdomTree BioRevolution Fund: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
25%
12 shared positions
Fee gap
30 bp
WDNA is cheaper
1-year return gap
25.3 pts
ARKG is ahead
Larger fund
ARKG
$2.1B
Side by side
| ARKG | WDNA | |
|---|---|---|
| Fund | ARK Genomic Revolution ETF | WisdomTree BioRevolution Fund |
| Issuer | ARK | WisdomTree |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.75% | 0.45% |
| Assets | $2.1B | $4.7M |
| Average daily dollar volume | $228M | $69K |
| Listed | Oct 31, 2014 | Jun 1, 2021 |
| FrenzyCap score | 57 | 41 |
| 1-month return | +13.1% | +6.3% |
| 3-month return | +26.4% | +15.9% |
| Year to date | +77.1% | +39.3% |
| 1-year return | +59.7% | +34.4% |
| 30-day volatility | 49.8% | 33.1% |
| Worst drawdown, 1 year | −27.5% | −11.7% |
| Trailing 12-month yield | — | 3.28% |
| Holdings | 34 | 81 |
| Top 10 weight | 58.3% | 30.7% |
| Look-through P/E | — | — |
| Holdings vs fair value | −0.9% | +5.0% |
| Holdings above 200-day average | 92% | 67% |
| Net flow, latest 3 reported months | −$3.3M thru Jul 2026 | $0 thru Jun 2026 |
| 30-day implied volatility | 53.5% | 34.2% |
| Holdings as of | as of Oct 9, 2026issuer data | as of Jun 30, 2026SEC filing |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
55% of ARKG · 25% of WDNA
Sector mix of the stock holdings
| Sector | ARKG | WDNA | Gap |
|---|---|---|---|
| Health Care | 71.7% | 70.9% | +0.7% |
| Technology | 26.3% | 7.2% | +19.1% |
| Consumer Staples | 0.0% | 4.2% | −4.2% |
| Materials | 0.0% | 1.2% | −1.2% |
More: full overlap table · ARKG holdings · WDNA holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.